Revealing Soon: A Potential Huge Investing Opportunity for Investors
Here is the latest financial fact sheet of REMUS PHARMA. For more details, see the REMUS PHARMA quarterly results and REMUS PHARMA share price.
1 Day | % | -2.4 |
No. of shares | m | 1.47 |
1 Week | % | 1.1 |
1 Month | % | 18.0 |
1 Year | % | - |
52 week H/L | Rs | 8,747.0/1,711.3 |
No. of Mths Year Ending |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
REMUS PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | NA | NA | NA | NA | ||
Low | Rs | NA | NA | NA | NA | ||
Sales per share (Unadj.) | Rs | 11,919.0 | 18,418.0 | 246.9 | 413.1 | ||
Earnings per share (Unadj.) | Rs | 812.0 | 1,026.0 | 34.3 | 78.0 | ||
Diluted earnings per share | Rs | 5.5 | 7.0 | 23.3 | 57.7 | ||
Cash flow per share (Unadj.) | Rs | 918.0 | 1,201.0 | 35.9 | 82.4 | ||
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 2.00 | ||
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 1.48 | ||
Avg Dividend yield | % | 0 | 0 | 0 | 0 | ||
Book value per share (Unadj.) | Rs | 2,020.0 | 3,046.0 | 65.8 | 175.6 | ||
Adj. book value per share | Rs | 13.7 | 20.7 | 44.7 | 129.9 | ||
Shares outstanding (eoy) | m | 0.01 | 0.01 | 1.00 | 1.09 | ||
Price / Sales ratio | x | 0 | 0 | 0 | 0 | ||
Avg P/E ratio | x | 0 | 0 | 0 | 0 | ||
P/CF ratio (eoy) | x | 0 | 0 | 0 | 0 | ||
Price / Book Value ratio | x | 0 | 0 | 0 | 0 | ||
Dividend payout | % | 0 | 0 | 0 | 2.6 | ||
Avg Mkt Cap | Rs m | 0 | 0 | 0 | 0 | ||
Total wages/salary | Rs m | 29 | 30 | 34 | 55 |
REMUS PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 119 | 184 | 247 | 450 | ||
Other income | Rs m | 9 | 8 | 7 | 16 | ||
Total revenues | Rs m | 128 | 192 | 254 | 466 | ||
Gross profit | Rs m | 4 | 8 | 41 | 105 | ||
Depreciation | Rs m | 1 | 2 | 2 | 5 | ||
Interest | Rs m | 0 | 0 | 1 | 2 | ||
Profit before tax | Rs m | 11 | 14 | 46 | 114 | ||
Minority Interest | Rs m | 0 | 0 | 0 | 0 | ||
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | ||
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | ||
Tax | Rs m | 3 | 3 | 12 | 29 | ||
Profit after tax | Rs m | 8 | 10 | 34 | 85 | ||
Gross profit margin | % | 3.3 | 4.1 | 16.7 | 23.4 | ||
Effective tax rate | % | 25.8 | 24.5 | 25.6 | 25.5 | ||
Net profit margin | % | 6.8 | 5.6 | 13.9 | 18.9 |
REMUS PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 48 | 75 | 77 | 113 | ||
Current liabilities | Rs m | 29 | 77 | 92 | 82 | ||
Net working cap to sales | % | 15.4 | -1.0 | -6.0 | 7.1 | ||
Current ratio | x | 1.6 | 1.0 | 0.8 | 1.4 | ||
Inventory Days | Days | 0 | 61 | 116 | 167 | ||
Debtors Days | Days | 498 | 714 | 431 | 393 | ||
Net fixed assets | Rs m | 5 | 35 | 81 | 232 | ||
Share capital | Rs m | 0 | 0 | 10 | 11 | ||
"Free" reserves | Rs m | 20 | 30 | 56 | 181 | ||
Net worth | Rs m | 20 | 30 | 66 | 191 | ||
Long term debt | Rs m | 3 | 2 | 1 | 71 | ||
Total assets | Rs m | 53 | 110 | 158 | 345 | ||
Interest coverage | x | 26.4 | 39.8 | 54.0 | 50.0 | ||
Debt to equity ratio | x | 0.1 | 0.1 | 0 | 0.4 | ||
Sales to assets ratio | x | 2.3 | 1.7 | 1.6 | 1.3 | ||
Return on assets | % | 16.2 | 9.7 | 22.3 | 25.3 | ||
Return on equity | % | 40.2 | 33.7 | 52.2 | 44.4 | ||
Return on capital | % | 49.4 | 43.0 | 70.4 | 44.4 | ||
Exports to sales | % | 0 | 0 | 0 | 0 | ||
Imports to sales | % | 0 | 0 | 2.0 | 1.1 | ||
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | ||
Imports (cif) | Rs m | 0 | 0 | 5 | 5 | ||
Fx inflow | Rs m | 119 | 153 | 232 | 440 | ||
Fx outflow | Rs m | 3 | 2 | 11 | 18 | ||
Net fx | Rs m | 116 | 151 | 220 | 422 |
REMUS PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 13 | 28 | 50 | 53 | ||
From Investments | Rs m | -6 | -31 | -45 | -152 | ||
From Financial Activity | Rs m | 1 | -1 | -2 | 118 | ||
Net Cashflow | Rs m | 8 | -4 | 3 | 19 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Swapnil Jatinbhai Shah | COMP SEC: Deval Bakulkumar Patel | YEAR OF INC: 2015 | NSE CODE: 788377 | FV (Rs): 10 | DIV YIELD (%): 0.0 |
More Trading Company Fact Sheets: BHANSALI ENG SUPREME PETR VIKAS LIFECARE STYRENIX PERFORMANCE MANALI PETRO
Compare REMUS PHARMA With: BHANSALI ENG SUPREME PETR VIKAS LIFECARE STYRENIX PERFORMANCE MANALI PETRO
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended on firm footing.